These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34053457)

  • 1. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab.
    Shibuya R; Baba K; Furuta R; Maesaka H; Hirosawa H; Bando T; Oshima A; Onoda H; Nukui T; Dougu N; Joho S; Nakatsuji Y
    Intern Med; 2024 Aug; 63(15):2193-2198. PubMed ID: 38171860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
    Fazal M; Prentice DA; Kho LK; Fysh E
    Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
    Chen JH; Lee KY; Hu CJ; Chung CC
    Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
    Soman B; Dias MC; Rizvi SAJ; Kardos A
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
    Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
    Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
    Wang C; Zeng H; Fang W; Song L
    Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
    Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
    Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.